Treatment of Refractory and Relapsed Adult Acute Leukemia Using a Uniform Chemotherapy Protocol

References

• Mayer R. J. Current chemotherapeutic treatment approaches to the management of previously untreated adults with de novo acute myelogenous leukemia. Sem. Oncol. 1987; 14: 384–396
   PubMed Web of Science ®Google Scholar
• Hoelzer D., Gale R. P. Acute lymphoblastic leukemia in adults: recent progress, future directions. Sem. He-matol. 1987; 24: 27–33
   PubMed Web of Science ®Google Scholar
• Bradstock K. F., Enno A., Hughes O., et al. Treatment results in adolescent and adult acute lymphoblastic leukaemia using a uniform chemotherapy protocol. Leuk. Lymph. 1991; 4: 317–324
   PubMed Web of Science ®Google Scholar
• Bezwoda W. R., Seymour L., Ariad S., MacPhail P. Acute lymphoblastic leukaemia in adults. Prognostic factors and 10 year treatment results. Leuk. Lymph. 1991; 4: 347–355
   Web of Science ®Google Scholar
• Preisler H. D., Anderson K., Rai K., et al. The frequency of long-term remission in patients with acute myelogenous leukemia treated with conventional maintenance chemotherapy. A study of 760 patients with a minimum follow-up time of 6 years. Br. J. Haematol. 1989; 71: 189–194
   PubMed Web of Science ®Google Scholar
• Herzig R. H., Wolff S. N., Lazarus H. M., Phillips G. L., Karanes C., Herzig G. P. High-dose cytosine arabinoside therapy for refractory leukemia. Blood 1983; 62: 361–369
   PubMed Web of Science ®Google Scholar
• Van Prooijen H. C., Dekker A. W., Punt K. The use of intermediate dose cytosine arabinoside (IDAra-C) in the treatment of acute non-lymphocytic leukemia in relapse. Br. J. Haematol. 1984; 57: 291–299
   PubMed Web of Science ®Google Scholar
• Brito-Babapulle F., Catovsky D., Newland A. C., Goldman J. M., Gallon D. A. G. Treatment of acute myeloid leukemia with intermediate-dose cytosine arabinoside and mitoxantrone. Sem. Oncol. 1987; 14(Supp. 1)51–52
   PubMedGoogle Scholar
• Hiddemann W., Kreutzmann H., Straif K., et al. High dose cytarabine and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia. Blood 1987; 69: 744–749
   PubMed Web of Science ®Google Scholar
• Walters R. S., Kantarjian H. M., Keating M. J., et al. Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia. Cancer 1988; 62: 677–682
   PubMed Web of Science ®Google Scholar
• Harousseau J. L., Reiffers J., Hurteloup P., et al. Treatment of relapsed acute myeloid leukaemia with idarubicin and intermediate dose cytarabine. J. Clin. Oncol. 1989; 7: 45–49
   PubMed Web of Science ®Google Scholar
• Lazzarino M., Morra E., Alessandrino E. P., et al. Mitoxantrone and etoposide: an effective regimen for refractory or relapsed acute myelogenous leukemia. Eur. J. He-matol. 1989; 43: 411–416
   PubMed Web of Science ®Google Scholar
• Hiddemann W., Aul C., Maschmeyer G., et al. High-dose versus intermediate-dose cytarabine combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age-adjusted randomized comparison. Sem. Hematol. 1991; 28(Supp. 4)35–38
   PubMedGoogle Scholar
• Arlin Z. A., Feldman E., Kempin S., et al. Amsa-crine with high-dose cytarabine is highly effective therapy for refractory and relapsed acute lymphoblastic leukemia in adults. Blood 1988; 72: 433–435
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Walters R. S., Keating M. J., Barlogie B., McCredie K. B., Freireich E. J. Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphoblastic leukemia. Cancer 1989; 64: 16–22
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Walters R. L., Keating M. J., et al. Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia. Cancer 1989; 65: 5–8
   Web of Science ®Google Scholar
• Milpied N., Gisselbrecht C., Harousseau J. L., et al. Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone and etoposide (PAME) chemotherapy. Cancer 1990; 66: 621–631
   Web of Science ®Google Scholar
• Hiddemann W., Büchner T., Heil G., et al. Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM). Leukemia 1990; 4: 637–640
   PubMed Web of Science ®Google Scholar
• Ciolli S., Leoni F., Caporale R., Salti F., Rossi Ferrini P., et al. Continuous-infusion cyclophosphamide plus vincristine, cytosine arabinoside and prednisone for refractory acute lymphoblastic leukemia in adults. Haematologica 1991; 76: 293–297
   PubMedGoogle Scholar
• Freund M., Diedrich H., Ganser A., et al. Treatment of relapsed or refractory adult acute lymphocytic leukemia. Cancer 1991; 69: 709, 16
   Web of Science ®Google Scholar
• Buchanan G. R., Rivera G. K., Boyett J. M., Chauvenet A. R., Crist W. M., Vietti T. J. Reinduction therapy in 297 children with acute lymphobiastic leukemia in first bone marrow relapse: A Pediatric Oncology Group Study. Blood 1988; 72: 1286–1292
   PubMed Web of Science ®Google Scholar
• Büchner T., Hiddemann W., Koenigsmann M., et al. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 1991; 78: 1190–1197
   PubMed Web of Science ®Google Scholar
• Andreeff M., Tafuri A., Hegewisch-Becker S. Colony stimulating factors (rh G-CSF, rh GM-CSF, rh IL-3x, and BCGF) recruit myeloblastic and lymphoblastic leukemic cells and enhance the cytotoxic effects of cytosine-arabinoside. Acute Leukemias: Prognostic Factors and Treatment strategies II, T. Büchner, G. Schellog, W. Hiddemann, et al. Springer Publishers, Berlin 1990; 747–762
   Google Scholar
• Bettelheim P., Valent P., Andreeff M., et al. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 1991; 77: 700–711
   PubMed Web of Science ®Google Scholar
• Jones L., Newland A. C. The management of relapsed and refractory acute myeloid leukemia in adults. Leuk. Lymph. 1991; 93–98
   PubMed Web of Science ®Google Scholar
• Hiddemann W., Buchner T. Treatment strategies in acute myeloid leukemia (AML): B. Second line treatment. Blut 1990; 60: 163–171
   PubMedGoogle Scholar